This site is intended for healthcare professionals

U.S. government commits to purchase approximately 1.7 million courses of molnupiravir upon issuance of Emergency Use Authorization or approval by the FDA.- Merck Inc.

Read time: 1 mins
Last updated:10th Jun 2021
Published:11th Jun 2021
Merck Inc., announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase III clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest